Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE

Biomedicine and Pharmacotherapy

Volumn 66, Issue 3, 2012, Pages 161-166

  Wang, Zhaohai ^a   Tang, Xuelian ^c   Zhang, Yilu ^d   Qi, Ruizhao ^a   Li, Zhiwei ^a   Zhang, Keming ^a   Liu, Zhenwen ^a   Yang, Xinying ^b  

^a BEIJING 302 HOSPITAL   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Cholangiocarcinoma; Lobaplatin

Indexed keywords

CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; LOBAPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLOBUTANES; DOWN-REGULATION; G0 PHASE; G1 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; ORGANOPLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862814414     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.09.008     Document Type: Article

References (25)

1. Khan S.A., Thomas H.C., Davidson B.R., et al. Cholangiocarcinoma. Lancet 2005, 366:1303-1314.
2. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41:5-15.
3. Blendis L., Halpern Z. An increasing incidence of cholangiocarcinoma: why?. Gastroenterology 2004, 127:1008-1009.
4. Shaib Y.H., El-Serag H.B., Davila J.A., et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005, 128:6206.
5. Tang H.H., Chang S., Wang X.W., et al. Diagnostic and surgical therapeutic features of extrahepatic bile duct carcinoma without jaundice. World J Gastroenterol 2004, 10:3060-3061.
6. Taylor-Robinson S.D., Toledano M.B., Arora S., et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001, 48:816-820.
7. McKeage M.J. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs 2001, 10:119-128.
8. Gietema J.A., de Vries E.G., Sleijfer D.T., et al. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 1993, 67:396-401.
9. Fiebig H.H., Hens H., Mross K. Phase I clinical trial of lobaplatin (D-19466) after intravenous bolus injection. Onkologie 1994, 17:142-148.
10. Dai HY, Liu L, Qin Sk, et al. Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell line LOVO in vitro. Biomedicine and pharmacotherapy 2011; ahead of publication.
11. Wu Q., Qin S.K., Teng F.M., et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J Hematol Oncol 2010, 3:43.
12. State food and drug administration database.[]. http://app1.sfda.gov.cn/datasearch/face3/base.jsp.
13. Ekholm S.V., Reed S.I. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Current opinion in cell biology. Curr Opin Cell Biol 2000, 12:676-684.
14. Hemann M.T., Lowe S.W. The p53-Bcl-2 connection. Cell Death Differ 2006, 13:1256-1259.
15. Rosen A., Casciola - Rosen L. Macromolecular substrates for the ICE-like proteases during apoptosis. J Cell Biochem 1997, 64:50-54.
16. Fiebig H., Berger D.P., Mross K., et al. Lobaplatin (D-19466): preclinical drug profile and results of the phase I study. Ann Oncol 1992, 3:143.
17. Gietema J.A., deVries E.G.E., Sleijfer D.T., et al. A phase I study of 1,2-diammine-cyclobutane-platinum (II) lactate (D- 19466, lobaplatin) administered daily for five days. J Cancer Res Clin Oncol 1991, 1176(Suppl. 3):S103.
18. Tsuruo T., Naito M., Tomida A., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Science 2003, 94:15-21.
19. Autret A., Martin S.J. Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol Cell 2009, 36:355-363.
20. Nicholson D.W., Thornberry N.A. Caspases: killer proteases. Trends Biochem Sci 1997, 22:299-306.
21. Walia V., Kakar S., Elble R. Micromanagement of the mitochondrial apoptotic pathway by p53. Front Biosci 2011, 16:749-758.
22. Pasetto L.M., D'Andrea M.R., Brandes A.A., et al. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol 2006, 60:59-75.
23. Voland C., Bord A., Péleraux A., et al. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 2006, 5:2149-2157.
24. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85.
25. Murray A.W. Recycling the cell cycle: cyclins revisited. Cell 2004, 116:221-234.